Molecular Basis and Diagnostic Approach to Isolated and Syndromic Lateralized Overgrowth in Childhood.

BWSp Beckwith-Wiedemann PIK3CA-related overgrowth spectrum PROS hemihyperplasia hemihypertrophy lateralized overgrowth

Journal

The Journal of pediatrics
ISSN: 1097-6833
Titre abrégé: J Pediatr
Pays: United States
ID NLM: 0375410

Informations de publication

Date de publication:
28 Jun 2024
Historique:
received: 14 04 2024
revised: 24 06 2024
accepted: 24 06 2024
medline: 1 7 2024
pubmed: 1 7 2024
entrez: 30 6 2024
Statut: aheadofprint

Résumé

To demonstrate a high-yield molecular diagnostic workflow for lateralized overgrowth (LO), a congenital condition with abnormal enlargement of body parts, and to classify it by molecular genetics. and STUDY DESIGN: We categorized 186 retrospective cases of LO diagnosed between 2003 and 2023 into suspected Beckwith-Wiedemann spectrum (BWSp), PIK3CA-Related Overgrowth Spectrum (PROS), vascular overgrowth (VO) , or isolated (ILO), based on initial clinical assessments, to determine the appropriate first-tier molecular tests and tissue for analysis. Patients underwent testing for 11p15 epigenetic abnormalities or somatic variants in genes related to PI3K/AKT/mTOR, vascular proliferation, and RAS-MAPK cascades using blood or skin DNA. For cases with negative initial tests, a sequential cascade molecular approach was employed to improve diagnostic yield. This approach led to a molecular diagnosis in 54% of cases, 89% of cases consistent with initial clinical suspicions and 11% reclassified. BWSp was the most common cause, with 43% of cases exhibiting 11p15 abnormalities. PROS had the highest confirmation rate, with 74% of clinically diagnosed patients showing a PIK3CA variant. VO demonstrated significant clinical overlap with other syndromes. Molecular diagnosis of ILO proved challenging, with only 21% of cases classifiable into a specific condition. Despite, LO is underdiagnosed from a molecular viewpoint and to date has had no diagnostic guidelines, which would be crucial for addressing potential cancer predisposition, enabling precision medicine treatments, or guiding management. This study sheds light on the molecular etiology of LO, highlighting the importance of tailored diagnostic approach and of selecting appropriate testing to achieve the highest diagnostic yield.

Identifiants

pubmed: 38945442
pii: S0022-3476(24)00280-4
doi: 10.1016/j.jpeds.2024.114177
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114177

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Simone Bellucca (S)

Postgraduate School of Pediatrics, University of Torino, Turin, Italy.

Diana Carli (D)

Department of Medical Sciences, University of Turin, Turin, Italy.

Andrea Gazzin (A)

Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin, Turin, Italy; Pediatric Clinical Genetics Unit, Regina Margherita Childrens' Hospital, Torino, Italy.

Stefania Massuras (S)

Pediatric Clinical Genetics Unit, Regina Margherita Childrens' Hospital, Torino, Italy; Department of Pediatric and Public Health Sciences, University of Torino, Torino, Italy.

Simona Cardaropoli (S)

Department of Pediatric and Public Health Sciences, University of Torino, Torino, Italy.

Maria Luca (M)

Department of Medical Sciences, University of Turin, Turin, Italy.

Paola Coppo (P)

Pediatric Dermatology Unit, Regina Margherita Childrens' Hospital, Torino, Italy.

Mirko Caprioglio (M)

Department of Pediatric and Public Health Sciences, University of Torino, Torino, Italy.

Roberta La Selva (R)

Pediatric Dermatology Unit, Regina Margherita Childrens' Hospital, Torino, Italy.

Marilidia Piglionica (M)

Medical Genetics Section, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University Hospital Consortium Corporation Polyclinics of Bari, Bari, Italy.

Piera Bontempo (P)

Laboratory of Medical Genetics, Molecular Genetics Unit, Bambino Gesù Children Hospital, IRCCS, Rome, Italy.

Gemma D'Elia (G)

Laboratory of Medical Genetics, Molecular Genetics Unit, Bambino Gesù Children Hospital, IRCCS, Rome, Italy.

Rosanna Bagnulo (R)

Medical Genetics Section, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University Hospital Consortium Corporation Polyclinics of Bari, Bari, Italy.

Giovanni Battista Ferrero (GB)

Department of Clinical and Biological Sciences, University of Torino, 10126 Torino, Italy.

Nicoletta Resta (N)

Medical Genetics Section, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University Hospital Consortium Corporation Polyclinics of Bari, Bari, Italy.

Alessandro Mussa (A)

Pediatric Clinical Genetics Unit, Regina Margherita Childrens' Hospital, Torino, Italy; Department of Pediatric and Public Health Sciences, University of Torino, Torino, Italy. Electronic address: alessandro.mussa@unito.it.

Classifications MeSH